🇺🇸 Compound Kushen Injection in United States

19 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Bilirubin Increased — 4 reports (21.05%)
  2. Anaemia — 2 reports (10.53%)
  3. Aspartate Aminotransferase Increased — 2 reports (10.53%)
  4. Blood Creatinine Increased — 2 reports (10.53%)
  5. Hypertriglyceridaemia — 2 reports (10.53%)
  6. Neutrophil Count Decreased — 2 reports (10.53%)
  7. Upper Respiratory Tract Infection — 2 reports (10.53%)
  8. Alanine Aminotransferase Increased — 1 report (5.26%)
  9. Ascites — 1 report (5.26%)
  10. Blood Alkaline Phosphatase Increased — 1 report (5.26%)

Source database →

Compound Kushen Injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Compound Kushen Injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Compound Kushen Injection in United States?

Beijing Zheng Ju Medical Technology Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.